儿童结核一线药物按WHO推荐体重带剂量和剂型的药代动力学
该研究在赞比亚和南非接受SHINE试验的儿童中,评估按WHO推荐体重带给予分散型儿科固定剂量复方片剂后一线抗结核药物的药代动力学。共77名儿童纳入,结果显示低体重带及≥25kg儿童中利福平、异烟肼和乙胺丁醇暴露低于成人,吡嗪酰胺暴露与成人相似。结论提示需进一步调整剂量以匹配成人目标暴露,乙胺丁醇当前剂量需进一步评估。
要点
- 低体重带儿童利福平、异烟肼和乙胺丁醇暴露低于成人。
- ≥25kg儿童接受成人剂量后利福平、异烟肼和乙胺丁醇暴露仍低于成人。
- 吡嗪酰胺暴露与成人相似,乙胺丁醇剂量需进一步评估。
核心结论
- 按WHO推荐体重带给予儿科固定剂量复方片剂后,低体重带和≥25kg儿童的一线抗结核药物暴露低于成人。
- 需进一步调整当前剂量以匹配成人目标暴露,乙胺丁醇当前剂量需进一步评估。
研究设计与样本
- 研究为在赞比亚和南非儿童中开展的药代动力学研究,数据来自治疗缩短SHINE试验。
- 共77名儿童纳入药代动力学评估,中位年龄3.7岁(四分位距1.4-6.6),40名(52%)为男性,20名(26%)为HIV阳性。
主要发现
- 利福平、异烟肼、吡嗪酰胺和乙胺丁醇的0-24小时血药浓度-时间曲线下面积中位数分别为32.5(四分位距20.1-45.1)、16.7(9.2-25.9)、317(263-399)和9.5(7.5-11.5)mg·h/L。
- 与成人相比,利福平暴露在4.0-7.9kg、8-11.9kg和≥25kg体重带儿童中更低。
- 异烟肼暴露在4.0-7.9kg和≥25kg体重带儿童中低于成人。
- 乙胺丁醇暴露在所有5个体重带儿童中均低于成人。
- 吡嗪酰胺暴露与成人相似。
关键数值与推荐
- 儿童体重4.0-7.9、8.0-11.9、12.0-15.9或16.0-24.9kg分别每日接受1、2、3或4片固定剂量复方片剂(利福平/异烟肼/吡嗪酰胺75/50/150mg,含或不含乙胺丁醇100mg,或利福平/异烟肼75/50mg)。
- 儿童体重25.0-36.9kg接受推荐用于成人<37kg的剂量:利福平300mg/d、异烟肼150mg/d、吡嗪酰胺800mg/d、乙胺丁醇550mg/d。
- 药代动力学在治疗至少2周后评估。
临床怎么用
- 临床使用WHO推荐体重带剂量和儿科固定剂量复方片剂时,应关注低体重带及≥25kg儿童利福平、异烟肼和乙胺丁醇暴露不足的风险。
- 乙胺丁醇当前推荐剂量在儿童中的暴露普遍低于成人,需进一步评估其合理性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dispersible pediatric fixed-dose combination (FDC) tablets delivering higher doses of first-line antituberculosis drugs in World Health Organization-recommended weight bands were introduced in 2015. We report the first pharmacokinetic data for these FDC tablets in Zambian and South African children in the treatment-shortening SHINE trial. METHODS: Children weighing 4.0-7.9, 8.0-11.9, 12.0-15.9, or 16.0-24.9 kg received 1, 2, 3, or 4 tablets daily, respectively (rifampicin/isoniazid/pyrazinamide [75/50/150 mg], with or without 100 mg ethambutol, or rifampicin/isoniazid [75/50 mg]). Children 25.0-36.9 kg received doses recommended for adults <37 kg (300, 150, 800, and 550 mg/d, respectively, for rifampicin, isoniazid, pyrazinamide, and ethambutol). Pharmacokinetics were evaluated after at least 2 weeks of treatment. RESULTS: In the 77 children evaluated, the median age (interquartile range) was 3.7 (1.4-6.6) years; 40 (52%) were male and 20 (26%) were human immunodeficiency virus positive. The median area under the concentration-time curve from 0 to 24 hours for rifampicin, isoniazid, pyrazinamide, and ethambutol was 32.5 (interquartile range, 20.1-45.1), 16.7 (9.2-25.9), 317 (263-399), and 9.5 (7.5-11.5) mg⋅h/L, respectively, and lower in children than in adults for rifampicin in the 4.0-7.9-, 8-11.9-, and ≥25-kg weight bands, isoniazid in the 4.0-7.9-kg and ≥25-kg weight bands, and ethambutol in all 5 weight bands. Pyrazinamide exposures were similar to those in adults. CONCLUSIONS: Recommended weight band-based FDC doses result in lower drug exposures in children in lower weight bands and in those ≥25 kg (receiving adult doses). Further adjustments to current doses are needed to match current target exposures in adults. The use of ethambutol at the current World Health Organization-recommended doses requires further evaluation.
引用
- Chabala C, Turkova A, Hesseling AC, et al. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations. Clin Infect Dis. 2022. PMID: 34420049. doi:10.1093/cid/ciab725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。